Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis

被引：0
|
作者：
Pardanani, A. D.
Caramazza, D.
George, G.
Lasho, T. L.
Hogan, W. J.
Litzow, M. R.
Begna, K.
Hanson, C. A.
McClure, R. F.
Bavisotto, L. M.
Smith, G.
Kowalski, M.
Sirhan, S.
Roberts, A. W.
Gupta, V.
Gotlib, J.
Tefferi, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Porta Clin PLLC, Seattle, WA USA
[3] YM BioSci, Mississauga, ON, Canada
[4] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[5] Royal Melbourne Hopsital, Parkville, Vic, Australia
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Pardanani, A.
    Laborde, R. R.
    Lasho, T. L.
    Finke, C.
    Begna, K.
    Al-Kali, A.
    Hogan, W. J.
    Litzow, M. R.
    Leontovich, A.
    Kowalski, M.
    Tefferi, A.
    LEUKEMIA, 2013, 27 (06) : 1322 - 1327
  • [2] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    R R Laborde
    T L Lasho
    C Finke
    K Begna
    A Al-Kali
    W J Hogan
    M R Litzow
    A Leontovich
    M Kowalski
    A Tefferi
    Leukemia, 2013, 27 : 1322 - 1327
  • [3] An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Litzow, Mark R.
    Hogan, William J.
    Begna, Kebede
    Smith, Gregg
    Bavisotto, Linda M.
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2011, 118 (21) : 1645 - 1645
  • [4] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [5] A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms
    Pardanani, Animesh
    George, Geeta
    Lasho, Terra
    Hogan, William J.
    Litzow, Mark R.
    Begna, Kebede
    Hanson, Curtis A.
    Fida, Rose
    Burns, Chris
    Smith, Gregg D.
    Tefferi, Ayalew
    BLOOD, 2010, 116 (21) : 206 - 206
  • [6] Discovery of CYT387: A potent and selective dual inhibitor of JAK1 and JAK2
    Burns, Christopher J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [7] Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis
    Xin, Yan
    Shao, Lixin
    Deng, Wei
    Niforos, Demi
    Kowalski, Mark
    Bavisotto, Linda M.
    Kawashima, Jun
    Jun, Susie
    Collins, Helen
    Ramanathan, Srinivasan
    BLOOD, 2013, 122 (21)
  • [8] Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD
    Bumm, Thomas G. P.
    Tyner, Jeffrey W.
    Deininger, Jutta
    Loriaux, Marc
    VanDyke, Jonathan
    Druker, Brian J.
    Burns, Christopher J.
    Fantino, Emmanuelle
    Deininger, Michael W. N.
    BLOOD, 2008, 112 (11) : 316 - 317
  • [9] CYT387, a Novel Jak1/Jak2 Inhibitor, Prevents Progression of Pulmonary Arterial Hypertension in the Rat Monocrotaline Model
    Zisman, Lawrence S.
    Jain, Ritu
    Chin-Dusting, Jaye
    Andrews, Karen
    Court, Naomi
    Fantino, Emmanuelle
    Farrugia, Michelle
    Burns, Christopher J.
    CIRCULATION, 2010, 122 (21)
  • [10] Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma
    Sparidans, Rolf W.
    Durmus, Selvi
    Xu, Ning
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 895 : 174 - 177
12345